Screener
Janux Therapeutics JANX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Net loss | $(46,333) | $(57,366) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 932 | 1,060 |
| Stock-based compensation | 18,331 | 21,662 |
| Accretion of discounts on investments, net | (5,510) | (9,427) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (149) | — |
| Prepaid expenses and other current assets | (2,955) | (1,049) |
Item 1. Financial Statements.
FAQ
- What is Janux Therapeutics's stock-based comp?
- Janux Therapeutics (JANX) reported stock-based comp of $3.78M in Q2 2026.
- How has Janux Therapeutics's stock-based comp changed year-over-year?
- Janux Therapeutics's stock-based comp decreased by 31.2% year-over-year, from $5.49M to $3.78M.
- What is the long-term trend for Janux Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Janux Therapeutics's stock-based comp has grown at a 49.8% compound annual growth rate (CAGR), from $6.91M to $34.75M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Janux Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude